Tu­mor gene ther­a­py de­vel­op­er re­brands, emerges with $30M from blue-chip in­vestors

A transat­lantic on­col­o­gy out­fit is en­ter­ing 2023 with a new look, name, of­fice space and $30 mil­lion to work with.

Akamis Bio — named af­ter Aka­mas, one of the war­riors in­side Greek mythol­o­gy’s Tro­jan horse — put word out on Thurs­day that it re­ceived $30 mil­lion in the form of a con­vert­ible note from a group of in­vestors co-led by ARCH, West­lake Vil­lage and the Park­er In­sti­tute for Can­cer Im­munother­a­py (PI­CI). That mon­ey will be fund the de­vel­op­ment of two clin­i­cal-stage pro­grams, NG-350A and NG-641, ac­cord­ing to a news re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER